Emilie Gauthy
Chief Technology Officer Zelluna
Seminars
Tuesday 24th February 2026
Aligning Science Strategy & Regulation: Bringing Off-the-Shelf TCR-NK Cell Therapies to Patients
11:00 am
- Navigating FDA and MHRA regulatory pathways through scientific advice to guide trial initiation and regulatory strategies for CTA
- Comparing regulatory expectations, challenges and opportunities for allogeneic NK cell therapies vs autologous T cell therapies
- Bringing “off-the-shelf” TCR-NK cell therapies into clinical trials providing multi-activation mechanisms to target solid tumours
